source
- Replimune to resubmit melanoma therapy RP1 to FDA after two prior rejectionsReplimune announced on Friday that it will again submit its advanced melanoma candidate, RP1, to the U.S. Food and Drug Administration for review. The company says the filing follows new discussion…
- Kenyan court halts U.S. plan for Ebola quarantine facility for AmericansA Nairobi High Court on Friday ordered a stop to a U.S. proposal to build a quarantine center in Kenya for Americans who might have been exposed to a rare Ebola strain circulating in northeastern C…